Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.57 |
| ▸ | RPS6KA1 | Q15418 | 9/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.51 |
| ▸ | AKT2 | P31751 | 5/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068507 | 0.94 | AKT1 (0.64) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL3487389 | 0.89 | AKT1 (0.56) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL3489269 | 0.89 | AKT1 (0.65) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL3488757 | 0.88 | AKT1 (0.66) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5063595 | 0.85 | AKT1 (0.62) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062747 | 0.84 | AKT1 (0.68) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5058517 | 0.82 | AKT1 (0.78) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL4247430 | 0.82 | AKT1 (0.66) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5063576 | 0.82 | AKT1 (0.85) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062740 | 0.82 | AKT1 (0.74) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | SMITHKLINE BEECHAM CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1954286-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1948185-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| WO-2007058879-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058852-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | MAP4K2, MAPKAPK2, PTK2B | AKT1 254/4885RPS6KA1 216/4885RPS6KA5 234/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.